Internet of Events
Leaderboard
Traders
Markets
Hot Bets
Surveillance
Pricing
Log in
Get Access
Accrue
/
Home
/
Manifold Markets
/
Will Mike Lustgarten start to regularly ANY of {rapamycin, metformin, acarbose, SGLT2 inhibitors) by the end of 2027?
Manifold
Active
BINARY · cpmm-1
Will Mike Lustgarten start to regularly ANY of {rapamycin, metformin, acarbose, SGLT2 inhibitors) by the end of 2027?
Yes
58%
Yes Pool
$121
No Pool
$198